person · Reporting owner

REARDON WILLIAM S

Disclosed activity across 3 companies

Tapewire entity: 140362
SEC CIK: 0001212646

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aceragen, Inc.IDRA · Entity 110652	Director	June 20, 2018	June 22, 2018
abrdn Healthcare Opportunities FundTHQ · Entity 5102	Director	February 25, 2021	March 01, 2021
abrdn World Healthcare FundTHW · Entity 5390	Director	April 06, 2021	April 08, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aceragen, Inc.

Report date June 20, 2018 · Filed June 22, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2028-06-20	Direct	50,000	Reported balance After 2018-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-20 · Grant · Acquired 50,000 · Balance 50,000 F1: These options were granted pursuant to the Company's director compensation on the date of the Company's 2018 annual meeting of stockholders at an exercise price to the closing price of the Company's common stock on the date of grant. F2: These options will vest in full and become immediately exercisable on the first anniversary of the date of grant, subject to continued service as director, and are granted under the Company's 2013 Stock Incentive Plan, as amended.

Filing footnotes · ownership attribution and instrument terms

F1: These options were granted pursuant to the Company's director compensation on the date of the Company's 2018 annual meeting of stockholders at an exercise price to the closing price of the Company's common stock on the date of grant.

F2: These options will vest in full and become immediately exercisable on the first anniversary of the date of grant, subject to continued service as director, and are granted under the Company's 2013 Stock Incentive Plan, as amended.

abrdn Healthcare Opportunities Fund

Report date February 25, 2021 · Filed March 01, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Shares of Beneficial InterestSEC Table I · non-derivative	Direct	1,196	Reported balance After 2021-02-25 transaction · row 1 1 source row Row 1 · 2021-02-25 · Purchase · Acquired 1,196 · Balance 1,196

abrdn World Healthcare Fund

Report date April 06, 2021 · Filed April 08, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Shares of Beneficial InterestSEC Table I · non-derivative	Direct	1,946	Reported balance After 2021-04-06 transaction · row 1 1 source row Row 1 · 2021-04-06 · Other · Acquired 486 · Balance 1,946
Subscription rightsSEC Table II · derivative / convertible security · Conversion / exercise price $14.26 · Expires 2021-04-06	Direct	0	Reported balance After 2021-04-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-04-06 · Other · Disposed 1,460 · Balance 0

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 06, 2021 Filed Apr 8, 2021 16:27 UTC	abrdn World Healthcare Fund THW · Entity 5390	OtherSubscription rights · Derivative	1,460	$0.00 Strike: $14.26	$0.00	Disclosure SEC source: 0001104659-21-048074 · tm2111500-3_4seq1.xml · derivative · entry 2 REARDON WILLIAM S · CIK 0001212646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Shares of beneficial Interest · 486 shares Expires 2021-04-06 Read SEC document
April 06, 2021 Filed Apr 8, 2021 16:27 UTC	abrdn World Healthcare Fund THW · Entity 5390	OtherShares of Beneficial Interest	486	$14.26	$6,931.33	Disclosure SEC source: 0001104659-21-048074 · tm2111500-3_4seq1.xml · nonDerivative · entry 1 REARDON WILLIAM S · CIK 0001212646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,946 Read SEC document
February 25, 2021 Filed Mar 1, 2021 17:36 UTC	abrdn Healthcare Opportunities Fund THQ · Entity 5102	PurchaseShares of Beneficial Interest	1,196	$20.85	$24,936.60	Disclosure SEC source: 0001104659-21-030170 · tm218331-2_4seq1.xml · nonDerivative · entry 1 REARDON WILLIAM S · CIK 0001212646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,196 Read SEC document
February 25, 2021 Filed Mar 1, 2021 17:34 UTC	abrdn World Healthcare Fund THW · Entity 5390	PurchaseShares of Beneficial Interest	1,460	$17.14	$25,024.40	Disclosure SEC source: 0001104659-21-030169 · tm218331-1_4seq1.xml · nonDerivative · entry 1 REARDON WILLIAM S · CIK 0001212646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,460 Read SEC document
June 20, 2018 Filed Jun 22, 2018 16:00 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantStock Options · Derivative	50,000	$1.53 Strike: $1.53	$76,500.00	Disclosure SEC source: 0001179110-18-008940 · edgar.xml · derivative · entry 1 REARDON WILLIAM S · CIK 0001212646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-20 F1 · security: These options were granted pursuant to the Company's director compensation on the date of the Company's 2018 annual meeting of stockholders at an exercise price to the closing price of the Company's common stock on the date of grant. F2 · derivative.exercise_date: These options will vest in full and become immediately exercisable on the first anniversary of the date of grant, subject to continued service as director, and are granted under the Company's 2013 Stock Incentive Plan, as amended. Read SEC document
July 03, 2017 Filed Jul 7, 2017 11:01 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantCommon Stock	7,714	$1.75	$13,499.50	Disclosure SEC source: 0001179110-17-010204 · edgar.xml · nonDerivative · entry 1 REARDON WILLIAM S · CIK 0001212646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,973 F1 · shares: This stock was issued to the reporting person pursuant to his election under the Issuer's director compensation program in lieu of cash. Read SEC document
June 07, 2017 Filed Jun 9, 2017 16:15 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantStock Options · Derivative	50,000	$0.00 Strike: $1.63	$0.00	Disclosure SEC source: 0001179110-17-008809 · edgar.xml · derivative · entry 1 REARDON WILLIAM S · CIK 0001212646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-07 F1 · security: These options were granted pursuant to the Company's director compensation on the date of the Company's 2017 annual meeting of stockholders at an exercise price to the closing price of the Company's common stock on the date of grant. F2 · derivative.exercise_date: These options will vest in full and become immediately exercisable on the first anniversary of the date of grant, subject to continued service as director, and are granted under the Company's 2013 Stock Incentive Plan, as amended. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.